Manal F Abdelmalek MD MD, MPH
Hepatology & Liver Transplantation
Professor of Medicine, Mayo Clinic, Rochester, MN
Join to View Full Profile
200 1st Street SWRochester, MN 55905
Dr. Abdelmalek is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1996 - 1998- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1992 - 1995
University of Missouri Kansas City School of MedicineClass of 1992
Certifications & Licensure
AZ State Medical License 1996 - Present
MN State Medical License 2022 - 2025
NC State Medical License 2006 - 2023
FL State Medical License 1998 - 2011
American Board of Internal Medicine Gastroenterology- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study Start of enrollment: 2007 Jul 01
- Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Start of enrollment: 2009 Apr 01
- PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsAlterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children.Cynthia A Moylan, Alisha M Mavis, Dereje Jima, Rachel Maguire, Mustafa Bashir
Epigenetics. 2022-11-01 - 30 citationsValidation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to othe...Tinsay A Woreta, Mark L Van Natta, Mariana Lazo, Arunkumar Krishnan, Brent A Neuschwander-Tetri
Plos One. 2022-01-01 - 68 citationsExpert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.Rohit Loomba, Vlad Ratziu, Stephen A. Harrison, Stefanie C. McFarlane, Nobuharu Tamaki
Gastroenterology. 2021-11-22
Journal Articles
- The Lancet Child & Adolescent HealthArun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
Press Mentions
5 Surprising Things to Know About Fatty Liver DiseaseMay 6th, 2022- Global Liver Institute’s International NASH Day 2021 Attracts Broad SupportJune 18th, 2021
Inventiva Achieves a Major Milestone by Completing Patient Recruitment for Its Phase IIb Clinical Study with Lanifibranor in NASHSeptember 4th, 2019- Join now to see all
Grant Support
- Impact Of Fructose On Metabolism, Energy Homeostasis And MR Biomarkers In NafldNational Institute Of Diabetes And Digestive And Kidney Diseases2012
- Hyperinsulinemia And Insulin Resistance In Fatty LiverNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2009
- Insulin Resistance In Nonalcoholic Fatty Liver Disease A Case Control StudyNational Center For Research Resources2006–2007
- Trial Of Betaine In PTS With Nonalcoholic SteatohepatisNational Center For Research Resources2005–2007
- Hyperinsulinemia And Insulin Resistance In Fatty LiverNational Institute Of Diabetes And Digestive And Kidney Diseases2005
- Trial Of Betaine In PTS With Nonalcoholic SteatohepatitisNational Center For Research Resources2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
